Brief: Moleculin Announces Additional Positive Preliminary Interim Data From Aml Clinical Trial

Moleculin Biotech

14/06/2024 13:06

June 14 (Reuters) - Moleculin Biotech Inc  MBRX.O :
    * MOLECULIN ANNOUNCES ADDITIONAL POSITIVE PRELIMINARY
INTERIM DATA
FROM AML CLINICAL TRIAL
    * 89% OF CRC'S WERE SUBJECTS WITH "POOR PROGNOSIS"
CYTOGENETICS
AND/OR MUTATIONS IN STUDY
    * CURRENT MEDIAN DURABILITY OF RESPONSE (MDOR) OF CRC'S = 6
MONTHS
AND INCREASING (N=9) IN STUDY
    * ANNAMYCIN CONTINUES TO DEMONSTRATE NO CARDIOTOXICITY
    * RECRUITMENT INCREASED TO 22 SUBJECTS AND CRC'S IN ALL
SUBJECTS
EVALUABLE FOR EFFICACY (N=20) WAS 45% IN STUDY

Source text for Eikon:  ID:nPnfgmGra 
Further company coverage:  MBRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))